USPTO Patent Grant: Bispecific Antibodies Targeting CD47 and PD-L1

The United States Patent and Trademark Office (USPTO) has issued patent US12583922B2, covering bispecific antibodies designed to target both CD47 and Programmed Death-Ligand 1 (PD-L1). The patent, assigned to Novimmune SA, includes claims related to the creation of these antibodies, the nucleic acids encoding them, and their therapeutic application in treating conditions involving malignant cells that express CD47 and/or PD-L1.

This patent grant signifies a new intellectual property right for Novimmune SA in the field of immuno-oncology. While patent grants are non-binding regulatory instruments, they can influence market exclusivity and R&D strategies for pharmaceutical and biotechnology companies. Companies operating in this space should be aware of this granted patent and its claims to ensure freedom to operate and to inform their own research and development efforts in similar therapeutic areas.